Flare Therapeutics is a biotechnology company that focuses on the discovery and development of small molecule drugs targeting transcription factors for the treatment of cancer and other diseases. The company uses its proprietary transcription factor drug discovery engine to identify small molecules that modulate transcription factors, which are key regulators of gene expression.
The company has six drug candidates in the pipeline, including its lead drug candidate FX-909, a small molecule inhibitor that targets the PPARG transcription factor in patients who have advanced urothelial (bladder) cancer. This program was expected to enter Phase I clinical trials in 2023. Furthermore, the company claims it is the first company slated to enter the clinic, making it a potentially groundbreaking development for urothelial cancer.
Key Customers and Partnerships
In April 2023, the company entered a multi-year strategic collaboration with molecular profiling company Caris Life Sciences to speed up precision medicine approaches across five of Flare's therapeutic programs.
Funding and Financials
In March 2023, the company raised USD 123 million in an oversubscribed Series B funding round co-led by GordonMD Global Investments LP and Pfizer Ventures. The new funds raised were used to finance a clinical trial scheduled for 2023, which woud involve testing its lead drug candidate FX-909. Additionally, the funds were used for the progress of a range of transcription factor targets in the field of oncology.
No investor data is available
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.